Cargando…

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin

Incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play a major role in regulation of postprandial glucose and the development of type 2 diabetes mellitus. The incretins are rapidly metabolized, primarily by the enzyme dipeptidyl‐peptidase 4 (DPP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balazki, Pavel, Schaller, Stephan, Eissing, Thomas, Lehr, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306617/ https://www.ncbi.nlm.nih.gov/pubmed/32543789 http://dx.doi.org/10.1002/psp4.12520

Ejemplares similares

A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors
por: Balazki, Pavel, et al.
Publicado: (2018)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion
por: McLaughlin, C. M., et al.
Publicado: (2021)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(−/−) mice by blocking monocyte/macrophage activation
por: Kahles, Florian, et al.
Publicado: (2018)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
por: Jonik, Szymon, et al.
Publicado: (2022)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP
por: Vidal, Oscar M., et al.
Publicado: (2022)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
por: Zhang, Zeqing, et al.
Publicado: (2017)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

GLP-1R Signaling and Functional Molecules in Incretin Therapy
por: Wan, Wenwei, et al.
Publicado: (2023)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE
por: LeValley, Stephanie L., et al.
Publicado: (2020)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
por: Ahrén, Bo
Publicado: (2023)

Molecular Pharmacology of the Incretin Receptors
por: Al-Sabah, Suleiman
Publicado: (2016)

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor
por: Goldsmith, Felicia, et al.
Publicado: (2015)

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
por: Marathe, Chinmay S., et al.
Publicado: (2011)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease
por: Wiciński, Michał, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5qavmkgs9lrtpbigu0e7aqggqs